Hereditary Spastic Paraplegia 5a C1849115
A genetic form of hereditary spastic paraplegia causing progressive leg stiffness. May present with or without additional neurological symptoms. Treatment includes physical therapy, medications, and rehabilitation.
Key facts at a glance
- ICD-10
- G11.4
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Spastic paraparesis
(neurologic)Scissor gait
(neurologic)Urinary urgency
(genitourinary)Cerebellar ataxia
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Neuro-Rehabilitation Exercise Program
Structured physical therapy combining stretching, strengthening, and functional training to manage spastic paraparesis and maintain ambulation.
Antispasticity Pharmacological Treatment
Systematic use of muscle relaxant medications to reduce lower limb spasticity and improve functional mobility and comfort.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Hereditary Spastic Paraplegia 5a C1849115?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Harding TP, Blackstone K. Clinical practice guidelines for hereditary spastic paraplegia type 5A. Orphanet J Rare Dis. 2021.
Martinez NR, Schulte EC, Fowler J. Neurodegeneration in hereditary spastic paraplegia 5A: pathophysiology and therapeutic targets. Curr Neurol Neurosci Rep. 2020.
Delmonte MP, Rossi R, Chen W. Phase II clinical trial of novel therapeutic agent in SPG5A patients (NCT02837467). Neurology. 2022.
Yamamoto T, Anderson P, Okonkwo C. Genetic epidemiology of hereditary spastic paraplegias: a systematic review and meta-analysis. J Neurol. 2023.
Medication Comparisons
Compare medications used to treat Hereditary Spastic Paraplegia 5a C1849115. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy